Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 8/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 3/20 | 0.35 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.34 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27199516 | 0.87 | KDM4E (0.35) | TRPA1KDM4E | |
| SCHEMBL27199568 | 0.85 | PTGDR2 (0.35) | PTGDR2TRPA1LIPGNTRK1KMT2A | |
| SCHEMBL30895065 | 0.85 | CNR2 (0.38) | TRPA1LIPGRAB9ASMN1; SMN2KDM4E | |
| SCHEMBL27199319 | 0.81 | TP53 (0.39) | KMT2AGAARAB9AKDM4EALDH1A1 | |
| SCHEMBL27199393 | 0.80 | KDM4E (0.36) | PTGDR2KMT2AMEN1GAARAB9A | |
| SCHEMBL27199440 | 0.80 | GRM2 (0.36) | LMNA | |
| SCHEMBL27199631 | 0.77 | MAP3K5 (0.37) | — | |
| SCHEMBL27199407 | 0.77 | MAPT (0.36) | TRPA1NTRK1SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL27199304 | 0.76 | L3MBTL1 (0.39) | KMT2AMEN1GAARAB9AKDM4E | |
| Hydrochloric Acid SCHEMBL27199587 | 0.76 | MEN1 (0.33) | KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240124448-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124448-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | TYK2, JAK2, JAK1 | PTGDR2 3987/4885TRPA1 4800/4885LIPG 3674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.